167 related articles for article (PubMed ID: 12697941)
1. Clinical approaches to osseous metastases in prostate cancer.
Morris MJ; Scher HI
Oncologist; 2003; 8(2):161-73. PubMed ID: 12697941
[TBL] [Abstract][Full Text] [Related]
2. Bone metastases in prostate cancer: a targeted approach.
Storey JA; Torti FM
Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
[TBL] [Abstract][Full Text] [Related]
3. Targeting bone physiology for the treatment of metastatic prostate cancer.
Autio KA; Morris MJ
Clin Adv Hematol Oncol; 2013 Mar; 11(3):134-43. PubMed ID: 23598981
[TBL] [Abstract][Full Text] [Related]
4. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
5. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases.
Pandit-Taskar N; Batraki M; Divgi CR
J Nucl Med; 2004 Aug; 45(8):1358-65. PubMed ID: 15299062
[TBL] [Abstract][Full Text] [Related]
6. Natural history and treatment of bone complications in prostate cancer.
Saad F; Clarke N; Colombel M
Eur Urol; 2006 Mar; 49(3):429-40. PubMed ID: 16431012
[TBL] [Abstract][Full Text] [Related]
7. [Current diagnosis and the multidisciplinary approach to the treatment of bone metastases in patients with prostate cancer].
Satoh T; Ishiyama H
Nihon Rinsho; 2016 Jan; 74(1):129-36. PubMed ID: 26793893
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.
Loberg RD; Logothetis CJ; Keller ET; Pienta KJ
J Clin Oncol; 2005 Nov; 23(32):8232-41. PubMed ID: 16278478
[TBL] [Abstract][Full Text] [Related]
9. Bone-directed treatments for prostate cancer.
Saad F
Hematol Oncol Clin North Am; 2006 Aug; 20(4):947-63. PubMed ID: 16861125
[TBL] [Abstract][Full Text] [Related]
10. The treatment of osseous metastases of hormone-refractory prostate cancer with external beam radiotherapy and Strontium-89.
De Ruysscher D; Spaas P; Specenier P
Acta Urol Belg; 1996 Sep; 64(3):13-9. PubMed ID: 8946776
[TBL] [Abstract][Full Text] [Related]
11. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer.
Logothetis CJ; Navone NM; Lin SH
Clin Cancer Res; 2008 Mar; 14(6):1599-602. PubMed ID: 18347159
[TBL] [Abstract][Full Text] [Related]
12. Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis.
Park SH; Keller ET; Shiozawa Y
Calcif Tissue Int; 2018 Feb; 102(2):152-162. PubMed ID: 29094177
[TBL] [Abstract][Full Text] [Related]
13. [Cytoreductive radical prostatectomy for prostate cancer with minimal osseous metastases: results of a first feasibility and case control study].
Heidenreich A; Pfister D; Brehmer B; Porres D
Urologe A; 2015 Jan; 54(1):14-21. PubMed ID: 25519996
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid.
Mystakidou K; Katsouda E; Parpa E; Vlahos L
J Pain Palliat Care Pharmacother; 2005; 19(3):41-5. PubMed ID: 16219610
[TBL] [Abstract][Full Text] [Related]
15. [Radiotherapy and bisphosphonate therapy in bone metastases of prostate carcinoma].
Seegenschmiedt MH; Oppenkowski R
Praxis (Bern 1994); 2001 Sep; 90(38):1645-52. PubMed ID: 11675918
[TBL] [Abstract][Full Text] [Related]
16. Heel pain as the inaugural manifestation of metastatic prostate cancer.
Gisserot O; Jaureguiberry JP; Carli P; Paris JF; Jaubert D; Chagnon A
Rev Rhum Engl Ed; 1996 Dec; 63(11):870-1. PubMed ID: 9010979
[No Abstract] [Full Text] [Related]
17. [Bone metastasis from prostate cancer].
Uemura M; Nonomura N
Clin Calcium; 2014 Aug; 24(8):1169-75. PubMed ID: 25065868
[TBL] [Abstract][Full Text] [Related]
18. Bone metastasis in prostate cancer: emerging therapeutic strategies.
Sturge J; Caley MP; Waxman J
Nat Rev Clin Oncol; 2011 Jun; 8(6):357-68. PubMed ID: 21556025
[TBL] [Abstract][Full Text] [Related]
19. Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined.
Lam MG; de Klerk JM; Zonnenberg BA
J Palliat Med; 2009 Jul; 12(7):649-51. PubMed ID: 19594354
[TBL] [Abstract][Full Text] [Related]
20. Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival.
Rove KO; Crawford ED
Oncology (Williston Park); 2011 Dec; 25(14):1362-70, 1375-81, 1387. PubMed ID: 22329188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
